ONCOGENE® will help to choose the best therapeutic options for solid tumours

ONCOGENE^®, a company that operates with a specialized service for genomic profiling and interpretation of tumours, has started operating in Moldova.

Cancer mortality rate could be reduced when the cancer is timely detected and treated effectively at an early stage.
Despite the fact that every medical oncologist strives for the most effective and safe treatment for their patients, at the same time, these goals are not always achieved.
The reason is the genetic uniqueness or uniqueness of each tumour of each patient, so that the "response to standard treatment” in patients with a tumour of the same localization is always different.

HOW SERVICE WORKS

After completing all the necessary documents and payment for service, Alfa Diagnostica Lab, which has a special agreement with ONCOGENE^® , will collect the blood sample and receives the FFPE Tumour Tissue Block from the patient.

• At the first stage, DNA is extracted and sequenced from the tumour and blood of patient (the exome is the protein - coding portion of the genome, consisting of > 25,000 genes)
• At the second stage, is used the special software – MH Guide^® (registered in the RM) the patient’s genomic data (> 30 GB of information) are analysed compared with the global biomedical and pharmacological data and knowledge from the proprietary DATAOME^® database
• At the third stage, an interactive MH Guide^® report is generated and then validated by the certified specialists in molecular pathology and oncology from Germany

The entire process (from submitting the biomaterial to receiving the report) takes approximately 3 weeks.

REPORT CONTENT

The MH Guide^® medical report includes: a description of detected mutations in the context of patient's cancer; a list of potentially effective and potentially ineffective medications based on the analysis of detected tumour mutations; and a list of medications with potential side effects based on the analysis of pharmacogenomics markers.

The MH Guide^® report is intended for medical oncologists who make decisions when selecting potentially effective and safe protocols of anticancer drug treatment.

MH Guide® este primul produs software al companiei Molecular Health (Heidelberg, Germania), înregistrat în Europa în calitate de dispozitiv medical In Vitro Diagnostic (CE-IVD) pentru a analiza și a interpreta datele genomice ale pacientului în scopul selecției unui tratament antitumoral potențial eficient și sigur. MH Guide® este utilizat în mod activ de medicii oncologi din Germania și din alte țări. Costul raportului este rambursat de către companiile de asigurări din Germania.

About Molecular Health GmbH

Molecular Health GmbH (Heidelberg, Germany) – the leading company in the computational Biomedicine, which deals with collection, integration and analysis of the biomedical data and knowledge to provide precision medicine (data science for precision medicine). The company provides comprehensive medical and therapeutic services to a wide range of clients, including doctors, hospitals, research networks, laboratories, regulators and pharmaceutical companies, using deep exploration of the big data. More than 10 years the company has been developing its own cloud technology platform Dataome^® and software Molecular Health Guide^® (MH Guide), using the platform SAP HANA, artificial intelligence and machine learning technology.

Official website of the company – www.molecularhealth.com